

Evaluation of Doramectin Injectable and Topical Crotamiton for the Treatment of Canine Demodicosis

Charn-Jin Lee, Min-Kyung Jeon, Young-Jae Choo¹, Ho-Jung Choi,
Keun-Ho Song, Seong-Mok Jeong, Young-won Lee, Seong-Jun Park*

College of Veterinary Medicine, Chungnam National University,

¹Dr. Choo's Animal Clinic, Daejeon

Canine demodicosis is one of the more common skin diseases encountered in veterinary practice. *Demodex canis* is a normal member of cutaneous ecology of the dog, but in some situations overpopulates resulting in skin disease. This study was designed to evaluate efficacy of doramectin injectable and topical crotamiton ointment for the treatment of generalized canine demodicosis.

Three dogs diagnosed with generalized demodicosis were enrolled in the study. On each dog, severe skin lesion was randomly selected to obtain deep skin scraping. An area under a coverslip measuring 18 X 18 mm was examined. All dogs were treated systemically with 0.6 mg/kg of the 1% doramectin formulation (Dectomax injectable[®], Pfizer animal health) and topically with 10% crotamiton ointment(Uracin[®], Green cross corp.). Follow-up visit were scheduled once a week for clinical evaluation and skin scrapings. The scraping sites were recored and sampled at each subsequent examination.

All dogs had a substantial reduction of clinical signs and numbers of *Demodex canis* mites on skin scrapings. All three had a marked clinical improvement after 2-3 months of doramectin therapy; however, two dogs remained pododemodicosis. Daily applications of topical crotamiton were successful to treat pododemodicosis.

This case report describes the efficacy of doramectin injectable and topical crotamiton for the treatment of canine demodicosis.

* Corresponding author: parksj@cnu.ac.kr